Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Core Insights - Nurix Therapeutics, Inc. has appointed Dr. Roger Dansey to its board of directors, enhancing the company's expertise in research, drug development, and commercialization [1][2] - Dr. Dansey brings over two decades of leadership experience in hematology and oncology, having held significant roles at Pfizer and Seagen [1][2] - Nurix is focused on targeted protein degradation medicines, aiming to innovate treatment options for cancer and autoimmune diseases [3] Company Overview - Nurix Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted protein degradation medicines [3] - The company's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on improving treatment for various cancers and autoimmune diseases [3] - Nurix's partnered drug discovery pipeline features collaborations with Gilead, Sanofi, and Pfizer, retaining options for co-development and profit sharing in the U.S. [3] Leadership and Expertise - Dr. Dansey's previous roles include Chief Development Officer and Chief Oncology Officer at Pfizer Oncology, and Chief Medical Officer at Seagen, where he contributed to the development of breakthrough cancer therapies [2] - His experience includes leadership positions at Merck, Gilead, and Amgen, where he was involved in the registration efforts for Keytruda and the development of Xgeva [2] - Dr. Dansey's appointment is expected to guide Nurix in accelerating pivotal trials for its lead asset, bexobrutideg, in chronic lymphocytic leukemia [2]